These findings emphasize the importance of considering cell type specificity, subcellular localization, and therapeutic context when interpreting SHP2 function—and when targeting SHP2 in both cancer and vascular disease [41,42,43] (Figure 5). This evidence concerns the gene PTPN11 and cancer.